Furthermore, IGF-1R’s involvement in modulating the tumor microenvironment, including interactions with immune cells, suggests that combining IGF-1 inhibitors with immunotherapies could bolster anti-tumor immune responses, offering a multi-pronged approach to combat BC. Here, IGF1 is linked to neoplasm.